Ankündigung • Apr 24
Chiome Bioscience Inc. to Report Q1, 2026 Results on May 14, 2026 Chiome Bioscience Inc. announced that they will report Q1, 2026 results on May 14, 2026 New Risk • Feb 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥593m revenue, or US$3.8m). Market cap is less than US$100m (JP¥8.49b market cap, or US$54.9m). Reported Earnings • Feb 14
Full year 2025 earnings released: JP¥14.47 loss per share (vs JP¥17.54 loss in FY 2024) Full year 2025 results: JP¥14.47 loss per share (improved from JP¥17.54 loss in FY 2024). Revenue: JP¥593.3m (down 24% from FY 2024). Net loss: JP¥982.8m (loss narrowed 3.7% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Ankündigung • Feb 10
Chiome Bioscience Inc., Annual General Meeting, Mar 27, 2026 Chiome Bioscience Inc., Annual General Meeting, Mar 27, 2026. Ankündigung • Dec 27
Chiome Bioscience Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026 Chiome Bioscience Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026 New Risk • Nov 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥996m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-JP¥996m free cash flow). Minor Risks Revenue is less than US$5m (JP¥728m revenue, or US$4.7m). Market cap is less than US$100m (JP¥8.37b market cap, or US$54.1m). Reported Earnings • Nov 17
Third quarter 2025 earnings released: JP¥3.82 loss per share (vs JP¥9.79 loss in 3Q 2024) Third quarter 2025 results: JP¥3.82 loss per share (improved from JP¥9.79 loss in 3Q 2024). Revenue: JP¥118.0m (down 26% from 3Q 2024). Net loss: JP¥260.0m (loss narrowed 26% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Oct 30
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: JP¥769m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (JP¥769m revenue, or US$5.0m). Market cap is less than US$100m (JP¥8.57b market cap, or US$55.6m). Reported Earnings • Aug 14
Second quarter 2025 earnings released: JP¥4.04 loss per share (vs JP¥4.63 loss in 2Q 2024) Second quarter 2025 results: JP¥4.04 loss per share. Revenue: JP¥113.1m (down 16% from 2Q 2024). Net loss: JP¥274.2m (loss widened 5.5% from 2Q 2024). Ankündigung • Aug 13
Chiome Bioscience Inc. to Report Q3, 2025 Results on Nov 11, 2025 Chiome Bioscience Inc. announced that they will report Q3, 2025 results on Nov 11, 2025 Ankündigung • May 31
Chiome Bioscience Inc. to Report Q2, 2025 Results on Aug 12, 2025 Chiome Bioscience Inc. announced that they will report Q2, 2025 results on Aug 12, 2025 Ankündigung • Mar 13
Chiome Bioscience Inc. to Report Q1, 2025 Results on May 12, 2025 Chiome Bioscience Inc. announced that they will report Q1, 2025 results on May 12, 2025 Reported Earnings • Feb 18
Full year 2024 earnings released: JP¥17.54 loss per share (vs JP¥24.62 loss in FY 2023) Full year 2024 results: JP¥17.54 loss per share (improved from JP¥24.62 loss in FY 2023). Revenue: JP¥780.8m (up 14% from FY 2023). Net loss: JP¥1.02b (loss narrowed 16% from FY 2023). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 13
Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2025 Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2025. Ankündigung • Dec 20
Chiome Bioscience Inc. Announces Publication on CBA-1205 Non-Clinical Data Chiome Bioscience Inc. announced that the research results were published in an international academic journal International Journal of Molecular Sciences. The paper discusses the findings on the non-clinical data for CBA-1205, a therapeutic antibody for cancer treatment currently in clinical trials at the company. In this study, CBA-1205, which selectively binds to delta-like 1 homolog (DLK1), destroyed cells expressed DLK1 through Antibody-Dependent Cellular Cytotoxicity (ADCC) activity. CBA-1205 also inhibited tumor growth on mouse-model transplanted with human liver cancer cells expressing DLK1. Furthermore, by combining with Lenvatinib, an standard of care of hepatocellular carcinoma, CBA-1205 inhibited tumor growth more effectively than single-dose administration in the same animal model. This combining effect of Lenvatinib and CBA-1205 lasted long during the observation period after the administration. In the toxicology study using cynomolgus monkeys, it showed no serious toxicological changes caused by the administration of CBA-1205. As a result of these findings, the paper discusses the potential of CBA-1205 as one of the treatment options for patients with hepatocellular carcinoma. Ankündigung • Nov 12
Chiome Bioscience Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025 Chiome Bioscience Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025 Reported Earnings • Aug 17
Second quarter 2024 earnings released: JP¥4.63 loss per share (vs JP¥9.00 loss in 2Q 2023) Second quarter 2024 results: JP¥4.63 loss per share (improved from JP¥9.00 loss in 2Q 2023). Revenue: JP¥134.1m (down 29% from 2Q 2023). Net loss: JP¥259.9m (loss narrowed 40% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Ankündigung • Aug 14
Chiome Bioscience Inc. to Report Q3, 2024 Results on Nov 12, 2024 Chiome Bioscience Inc. announced that they will report Q3, 2024 results on Nov 12, 2024 Ankündigung • Jun 13
Chiome Bioscience Inc. to Report Q2, 2024 Results on Aug 13, 2024 Chiome Bioscience Inc. announced that they will report Q2, 2024 results on Aug 13, 2024 Ankündigung • Mar 01
Chiome Bioscience Inc. to Report Q1, 2024 Results on May 14, 2024 Chiome Bioscience Inc. announced that they will report Q1, 2024 results on May 14, 2024 Reported Earnings • Feb 14
Full year 2023 earnings released: JP¥24.13 loss per share (vs JP¥28.26 loss in FY 2022) Full year 2023 results: JP¥24.13 loss per share (improved from JP¥28.26 loss in FY 2022). Revenue: JP¥682.5m (up 8.2% from FY 2022). Net loss: JP¥1.22b (loss narrowed 1.8% from FY 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Ankündigung • Feb 13
Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2024 Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2024. Ankündigung • Dec 05
Chiome Bioscience Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024 Chiome Bioscience Inc. announced that they will report fiscal year 2023 results at 3:00 PM, Tokyo Standard Time on Feb 13, 2024 New Risk • Nov 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Shareholders have been diluted in the past year (9.4% increase in shares outstanding). Revenue is less than US$5m (JP¥721m revenue, or US$4.9m). Market cap is less than US$100m (JP¥6.83b market cap, or US$46.2m). Reported Earnings • Nov 15
Third quarter 2023 earnings released: JP¥5.25 loss per share (vs JP¥5.79 loss in 3Q 2022) Third quarter 2023 results: JP¥5.25 loss per share (improved from JP¥5.79 loss in 3Q 2022). Revenue: JP¥165.1m (up 6.2% from 3Q 2022). Net loss: JP¥254.8m (flat on 3Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Ankündigung • Aug 27
Chiome Bioscience Inc. to Report Q3, 2023 Results on Nov 14, 2023 Chiome Bioscience Inc. announced that they will report Q3, 2023 results on Nov 14, 2023 Ankündigung • Jul 06
Chiome Bioscience Inc. announced that it expects to receive ¥13.49304 million in funding Chiome Bioscience Inc. announced that it has entered into an purchase agreement to issue 64,560 units of 19th stock acquisition rights and 32,280 units of 20th stock acquisition rights at a price of ¥171 yen per 19th stock acquisition right, ¥76 per 20th stock acquisition right for gross proceeds of ¥1,931,609,040 through third-party allotment on July 4, 2023. The stock acquisition rights are exercisable 19th Stock Acquisition Rights ¥175, 20th stock acquisition rights ¥247. There is no maximum strike price. The minimum exercise price is ¥129. The transaction will include participation from Growth Capital and Barclays Bank. The transaction has been approved in the board of directors' meeting of the company. The exercisable period of the stock acquisition rights will start from July 21, 2023 to July 22, 2025. The stock acquisition rights have a hold period and cannot be transferred without the company's approval. Ankündigung • Jun 02
Chiome Bioscience Inc. to Report Q2, 2023 Results on Aug 09, 2023 Chiome Bioscience Inc. announced that they will report Q2, 2023 results on Aug 09, 2023 Reported Earnings • Feb 17
Full year 2022 earnings released: JP¥28.26 loss per share (vs JP¥36.74 loss in FY 2021) Full year 2022 results: JP¥28.26 loss per share (improved from JP¥36.74 loss in FY 2021). Revenue: JP¥630.8m (down 12% from FY 2021). Net loss: JP¥1.24b (loss narrowed 16% from FY 2021). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Ankündigung • Feb 14
Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2023 Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2023. Ankündigung • Dec 28
Chiome Bioscience Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023 Chiome Bioscience Inc. announced that they will report fiscal year 2022 results on Feb 14, 2023 Reported Earnings • Nov 16
Third quarter 2022 earnings released: JP¥5.96 loss per share (vs JP¥10.77 loss in 3Q 2021) Third quarter 2022 results: JP¥5.96 loss per share (improved from JP¥10.77 loss in 3Q 2021). Revenue: JP¥155.5m (flat on 3Q 2021). Net loss: JP¥256.6m (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Audit & Supervisory Board Member Matsuo Kikuchi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 28
Chiome Bioscience Inc. to Report Q3, 2022 Results on Nov 14, 2022 Chiome Bioscience Inc. announced that they will report Q3, 2022 results on Nov 14, 2022 Reported Earnings • Aug 16
First half 2022 earnings released: JP¥18.17 loss per share (vs JP¥10.16 loss in 1H 2021) First half 2022 results: JP¥18.17 loss per share (down from JP¥10.16 loss in 1H 2021). Revenue: JP¥278.2m (down 28% from 1H 2021). Net loss: JP¥771.0m (loss widened 89% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Ankündigung • Jul 05
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial Chiome Bioscience Inc. announced that the first patient has been dosed CBA-1535 in a Phase I clinical trial. The first part of the trial will evaluate the safety, tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients. In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizumab. This first-in-human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center. Will continue to update the future process in a timely manner. Ankündigung • Jun 13
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study Chiome Bioscience Inc. announced that new contract with additional institutes had been finalized and the first patient has been dosed CBA-1205, the first-in-class antibody, in the second part (expansion part) of Phase I study. In the first part of Phase I study, CBA-1205 exhibited good safety and tolerability. In the second part, two doses will be given to the patients with hepatocellular carcinoma to evaluate safety and to determine the optimum dose for further development. Also, the exploratory efficacy and pharmacokinetics will be investigated. The study will be conducted at National Cancer Center Hospital, National Cancer Center Hospital East. Additional institutes will be at Kanagawa Cancer Center and Niigata University Medical and Dental Hospital. Ankündigung • Jun 02
Chiome Bioscience Inc. to Report Q2, 2022 Results on Aug 10, 2022 Chiome Bioscience Inc. announced that they will report Q2, 2022 results on Aug 10, 2022 Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Audit & Supervisory Board Member Matsuo Kikuchi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 08
Chiome Bioscience Inc. to Report Q1, 2022 Results on May 13, 2022 Chiome Bioscience Inc. announced that they will report Q1, 2022 results on May 13, 2022 Ankündigung • Feb 17
Chiome Bioscience Inc. Submits an Initial Application for Phase I Study on CBA-1535 Chiome Bioscience Inc. announced that it has submitted an initial application for a Phase I study on CBA-1535 to the Pharmaceuticals and Medical Devices Agency (PMDA) on February 16, 2022. CBA-1535 is a trispecific antibody binding to 5T4 which highly expresses on solid tumor cells and CD3 on the surface of immune T cells. It forms a synapse between both cells and activates patients' intrinsic T cells that leads to killing the cancer cells. (This mechanism is called"T cell engager".) CBA-1535 is produced by the trispecific antibody generation technology called as Tribody. This is the first-in human study of multi-specific antibody in Tribody and consists of 2 parts. The first part is a dose escalation to assess the safety and initial pharmacokinetics as a single agent. The second part is an expansion part where safety and preliminary efficacy are evaluated in combination with cancer immunotherapy agent. In addition to the safety and efficacy, obtaining proof of concept as a T cell engager is a major objective. Once it is proved Tribody technology could be applicable to multiple types of tumor antigen. After submission of the application all the common regulatory procedure will be proceeded. Reported Earnings • Feb 16
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥36.74 loss per share (down from JP¥36.06 loss in FY 2020). Revenue: JP¥712.9m (up 48% from FY 2020). Net loss: JP¥1.48b (loss widened 14% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Ankündigung • Feb 15
Chiome Bioscience Inc., Annual General Meeting, Mar 25, 2022 Chiome Bioscience Inc., Annual General Meeting, Mar 25, 2022. Ankündigung • Dec 24
Chiome Bioscience Inc. Announces Move to the Second Half Part of Phase 1 Clinical Trial of First-In-Class CBA-1205 Chiome Bioscience Inc. announced that it have successfully completed patient enrollment in the first part of phase I study of CBA-1205. CBA-1205 is the first in-class antibody which Chiome has been developing for cancer treatment. As a result of the safety evaluation, which is the primary objective of this part, Principal investigators and Chiome agreed with moving to the second part of phase I study to evaluate the safety and initial efficacy in patients with hepatocellular carcinoma. In the first part of the phase I study, which started in July 2020, the safety, tolerability, and pharmacokinetics of CBA-1205 were evaluated in patients with various solid tumors. This part is called "dose escalation part" where the patients are assigned to one of the several dose groups that are administered each dose in the order of the lowest to the dose to determine the dose that can be given safely without causing unacceptable side effects for the second part of the study. As the safety of this antibody has been proven to be high in the course of the first part, the original protocol was amended to add the higher dose groups to be administered. In December, enrollment in the first part of the phase I study of CBA-1205 has completed at The National Cancer Center Hospital and East Hospital. Principal investigators and Chiome concluded that this antibody was safe and well tolerated and that it was possible to conduct the second part of the study. In the second part, only patients with hepatocellular carcinoma will be enrolled and given CBA-1205 to evaluate safety and initial efficacy. CBA-1205 is an afucosylated humanized antibody targeting cell surface antigen "DLK-1 (Delta-like 1homolog)" which expresses on hepatocellular carcinoma and other solid cancers. CBA-1205 exhibits potent and specific anti-tumor activity in various DLK-1 expressing cancer models. DLK-1 is known to control the proliferation and differentiation of stem cells, progenitor cells, and other immature cells. CBA-1205 is expected to offer a new therapeutic option for the treatment of DLK-1 expressing cancer such as hepatocellular carcinoma. Ankündigung • Dec 16
Chiome Bioscience Inc. announced that it has received ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm On December 15, 2021, Chiome Bioscience Inc. closed the transaction. Ankündigung • Nov 30
Chiome Bioscience Inc. announced that it expects to receive ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm Chiome Bioscience Inc. announced that it has entered into an purchase agreement to issue 80,000 units of 18th stock acquisition rights at a price of ¥210 per stock for gross proceeds of ¥1,728,800,000 through third-party allotment on November 29, 2021. The stock acquisition rights are exercisable to purchase 8,000,000 shares which is equal to 100 shares per stock acquisition right at an initial exercise price of ¥215 per share. There is no maximum strike price. The minimum exercise price is ¥129. The transaction will include participation from SMBC Nikko Securities Inc., Investment Arm. The transaction has been approved in the board of directors' meeting of the company. The transaction is expected to close on December 15, 2021. The exercisable period of the stock acquisition rights will start from December 16, 2021 to December 19, 2023. The stock acquisition rights have a hold period and cannot be transferred without the company's approval. Reported Earnings • Aug 18
Second quarter 2021 earnings released: JP¥6.16 loss per share (vs JP¥9.25 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: JP¥138.9m (up 68% from 2Q 2020). Net loss: JP¥248.0m (loss narrowed 20% from 2Q 2020). Reported Earnings • May 16
First quarter 2021 earnings released: JP¥4.07 loss per share (vs JP¥12.78 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: JP¥246.1m (up 171% from 1Q 2020). Net loss: JP¥160.7m (loss narrowed 62% from 1Q 2020). Ankündigung • Feb 09
Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2021 Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2021. Ankündigung • Jan 31
Chiome Bioscience Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021 Chiome Bioscience Inc. announced that they will report fiscal year 2020 results on Feb 09, 2021 Ankündigung • Jan 15
Shanghai Henlius Biotech, Inc. Enters into Exclusive License Agreement with Chiome Bioscience Inc. for Development and Commercialization of the Anti-Tpor-2 Antibodies, Liv-2008/2008B Chiome Bioscience Inc. announced that Shanghai Henlius Biotech, Inc. has entered into Exclusive License Agreement with Chiome for development and commercialization of the anti-TPOR-2 antibodies, LIV-2008/2008b, generated by Chiome. Under the Exclusive License Agreement, Chiome will grant an exclusive license, with sublicensing rights, to Henlius concerning development, manufacturing and marketing in China (including Hong Kong Special Administrative Region and Macau Special Administrative Region and Taiwan region) for LIV-2008/2008b. In addition, Chiome grants to Henlius option rights concerning development, manufacturing and marketing of LIV-2008/2008b in the rest of the world other than the initial
terretory, China (including Hong Kong Special Administrative Region and Macau Special Administrative Region and Taiwan region). Chiome will receive USD 1 million as an upfront payment upon signing the Exclusive License Agreement. In case Henlius exercises the option rights as described above, the total value of the agreement which Henlius shall pay to Chiome will be USD 122.5 million . In addition, after the launch of LIV-2008/2008b or related products (Product), Chiome is eligible to receive royalties according to Henlius's amount of sales of the Product. Upon execution of this Agreement, the upfront payment shall be booked as sales of Drug Discovery and Development Business for the first quarter of the fiscal year ending December 31, 2021 and the impact on the business performance for this fiscal year is currently being considered. Is New 90 Day High Low • Jan 15
New 90-day high: JP¥241 The company is up 6.0% from its price of JP¥228 on 16 October 2020. The Japanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 10.0% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: JP¥203 The company is down 26% from its price of JP¥274 on 09 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 14% over the same period. Ankündigung • Nov 11
Chiome Bioscience Inc. Announces Amendment to the License Agreement with ADC Therapeutics Chiome Bioscience Inc. announced that it has agreed with ADC Therapeutics SA to make an amendment to the License Agreement of September 27, 2017 under which Chiome granted ADCT the worldwide, exclusive, sub-licensable right to anti-DLK-1 antibody including LIV-1205 for the development, manufacture and commercialization in Antibody-Drug Conjugates (ADC) fields. With this amendment, both parties agreed that ADCT's exclusivity would be related to Pyrrolobenzodiazepine (PBD)-based ADC development only an area where ADCT has the exclusive proprietary rights to develop a PBD-based ADC targeting DLK-1, and in particular development of ADCT-701. This amendment allows Chiome to develop ADCs not incorporating a PBD-based ADC and gives Chiome greater flexibility in advancing strategic drug development of an anti-DLK-1 antibody, and to pursue the business potential of CBA-1205, including licensing opportunites, which is currently undergoing Phase 1 clinical trial. The amendment also restructured financial terms between the parties. There is no impact on the financial performance in the fiscal period ending December 31, 2020. Ankündigung • Aug 30
Chiome Bioscience Inc. to Report Q3, 2020 Results on Nov 10, 2020 Chiome Bioscience Inc. announced that they will report Q3, 2020 results on Nov 10, 2020 Ankündigung • Jun 28
Chiome Bioscience Inc. to Report Q2, 2020 Results on Aug 11, 2020 Chiome Bioscience Inc. announced that they will report Q2, 2020 results on Aug 11, 2020